<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992143</url>
  </required_header>
  <id_info>
    <org_study_id>HEPIC2004</org_study_id>
    <nct_id>NCT04992143</nct_id>
  </id_info>
  <brief_title>TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC</brief_title>
  <official_title>The Efficacy and Safety of TACE Combined With Tilelizumab and Sorafenib in Treating BCLC Stage C HCC Patients: a Single-center, Single-arm, Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BeiGene (Beijing) Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the BCLC staging system treatment recommendation, systemic treatment is&#xD;
      recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for&#xD;
      patients in this stage. Studies have shown that TACE combined with sorafenib therapy has&#xD;
      shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also&#xD;
      shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve&#xD;
      the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed&#xD;
      to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in&#xD;
      the treatment of BCLC stage C liver cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>at 1 year after enrolled</time_frame>
    <description>1-year survival rate assessed by Kaplan-Meier analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>at 12 weeks and up to 2 years after enrolled</time_frame>
    <description>Time to progression assessed by independent radiologic review according to mRECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>at 12 weeks and up to 2 years after enrolled</time_frame>
    <description>Progression free survival assessed by independent radiologic review according to mRECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>at 12 weeks and up to 2 years after enrolled</time_frame>
    <description>Objective response rate assessed by independent radiologic review according to mRECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>at 12 weeks and up to 2 years after enrolled</time_frame>
    <description>Disease control rate assessed by independent radiologic review according to mRECIST criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>BCLC Stage C Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>TACE combined Tilelizumab and Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TACE first combined Tilelizumab(240mg/3wks ivgtt） and Sorafenib （800mg/day orally)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>TACE first ,and more TACE could be performed when it is necessary.</description>
    <arm_group_label>TACE combined Tilelizumab and Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tilelizumab</intervention_name>
    <description>Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE</description>
    <arm_group_label>TACE combined Tilelizumab and Sorafenib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE</description>
    <arm_group_label>TACE combined Tilelizumab and Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Child-Pugh score≤ 7&#xD;
&#xD;
          -  HCC diagnosed by biopsy or by the noninvasive criteria of the Chinese Liver Cancer&#xD;
             Guideline 2019&#xD;
&#xD;
          -  the primary HCC being in BCLC C stage according to NCCN guideline&#xD;
&#xD;
          -  No previous systemic therapy for HCC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diffuse HCC&#xD;
&#xD;
          -  Uncontrolled ascites of hepatic encephalopathy&#xD;
&#xD;
          -  Prior liver transplantation&#xD;
&#xD;
          -  Positive for human immunodeficiency virus&#xD;
&#xD;
          -  Active gastric or duodenal ulcer&#xD;
&#xD;
          -  Other uncontrolled comorbidities or malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun-hui Sun, MD,PH.D</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-hui Sun, MD,PH.D</last_name>
    <phone>+86-0571-87236815</phone>
    <email>1307005@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tong-yin Zhu, MD</last_name>
    <phone>+86-0571-87236812</phone>
    <email>1513001@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun-hui Sun, MD,PH.D</last_name>
      <phone>+86-0571-87236815</phone>
      <email>1307005@zju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Tong-yin Zhu, MD</last_name>
      <phone>+86-0571-87236812</phone>
      <email>1513001@zju.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCLC Stage C</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Transarterial Chemoembolization</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Tilelizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

